Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

First 500 patients in Align-AR trial using TAVR for pure aortic regurgitation show strong outcomes
Raj Makkar, MD, Cedars-Sinai, explains the late-breaking data from the Align-AR trial on the first 500 patients treated for aortic regurgitation using the Jena Valve TAVR device.
5-year Evolut Low Risk Data: Durable clinical outcomes, outstanding valve performance
The late-breaking five-year results of the Evolut Low-Risk Trial presented at the American College of Cardiology (ACC) 2025 meeting in late March, showed positive results for the Evolut transcatheter aortic valve replacement (TAVR) system vs. surgical aortic valve replacement (SAVR).
FDA clears new device for enabling access to the heart’s surface without an exposed needle
CardioVia's ViaOne technology includes a blunt-tip needle that remains concealed to help interventional cardiologists and electrophysiologists treat cardiac arrhythmias with a reduced risk of perforation or any other complications.
Late-breaking cardiovascular drug trials took center stage at ACC.25
Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.
Deaths after TAVR are on the rise: Is the pandemic to blame or should cardiologists be concerned?
COVID-19 may help explain the increased rates of cardiac and noncardiac mortality among TAVR patients, but there are several other factors to consider as well. Researchers explored nearly 11 years of STS/ACC registry data to learn more.

AKI following LAAC ‘relatively frequent,’ tied to worse midterm outcomes

Acute kidney injury (AKI) occurs in about 9 percent of patients undergoing left atrial appendage closure (LAAC) and is associated with greater odds of downstream mortality and embolic events, according to a study published June 4 in JACC: Cardiovascular Interventions.

Getinge announces results from SEMPER FI pilot study of intra-aortic balloon pump showing numerical trend toward reduced mortality in patients with extensive myocardial infarction and persistent ischemia

WAYNE, N.J., May 25, 2018 — Getinge, a leading global provider of innovative medical technology, today announced results from the Survival Improvement in Extensive Myocardial Infarction with PERsistent Ischemia Following IABP Implantation (SEMPER FI) pilot study.

Baby born with 'half a heart' overcomes 2 open-heart surgeries

At just 5-months-old, Luke Pilkinton has survived what most would hope never to experience in a lifetime. He was born with hypoplastic left heart syndrome—a rare and deadly congenital defect, that affects 960 babies born in the U.S. every year.

Independent Stent Imaging Study Shows Excellent Healing Profile with Resolute Onyx DES in Complex Patients with Coronary Artery Disease

DUBLIN and PARIS — May 24, 2018 — Investigators today unveiled clinical data from the independently run Onyx 1-Month OCT Study, which showed strong early vessel healing in a patient population that contained a high percentage of patients with complex coronary artery disease who were implanted with the Resolute Onyx(TM) DES at one-month follow-up.

Many operators don’t use FFR, iFR because they think angiography is good enough

Assessment of coronary physiology to guide revascularization decisions has been linked to lower adverse event rates than using angiography alone, but the adoption of techniques such as fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) continues to lag behind guideline recommendations.

FDA clears pulmonary embolism thrombectomy device

The FlowTriever System has become the first thrombectomy device designed to treat pulmonary embolism (PE) to be cleared by the FDA, Inari Medical announced in a May 21 press release.

New ORBITA data: Freedom from angina, stress echos improved with PCI

At EuroPCR in Paris, investigators of the controversial ORBITA trial presented two previously unreported benefits of percutaneous coronary intervention (PCI) for the study population.

East African hospitals first from region to join ACC’s registry program

Two hospitals in East Africa have announced participation in the American College of Cardiology’s CathPCI registry, which aims to assess treatments and outcomes related to cardiac catheterization and percutaneous coronary interventions (PCIs).

Interventional Cardiology

First 500 patients in Align-AR trial using TAVR for pure aortic regurgitation show strong outcomes

5-year Evolut Low Risk Data: Durable clinical outcomes, outstanding valve performance

FDA clears new device for enabling access to the heart’s surface without an exposed needle

Late-breaking cardiovascular drug trials took center stage at ACC.25

Deaths after TAVR are on the rise: Is the pandemic to blame or should cardiologists be concerned?